Provenance Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Provenance Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Buy	201 +1	+0.5%	+$681	0.01%	167
2026 Q1	$155K	Hold	200	–	–	0.02%	136
2025 Q4	$154K	Hold	200	–	–	0.02%	128
2025 Q3	$112K	Hold	200	–	–	0.01%	160
2025 Q2	$105K	Hold	200	–	–	0.02%	162
2025 Q1	$127K	Hold	200	–	–	0.02%	164
2024 Q4	$142K	Hold	200	–	–	0.02%	166
2024 Q3	$210K	Hold	200	–	–	0.03%	151
2024 Q2	$210K	Hold	200	–	–	0.03%	137
2024 Q1	$192K	Hold	200	–	–	0.03%	148
2023 Q4	$176K	Hold	200	–	–	0.02%	133
2023 Q3	$165K	Buy	+200	New	+$157K	0.03%	126

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Provenance Wealth Advisors's REGN Position: Q2 2026 in Review

Provenance Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.5% in Q2 2026, buying an estimated $681 and bringing the position to 201 shares worth $125K. The position accounts for 0.01% of the portfolio, ranked #167.

Provenance Wealth Advisors first reported a position in REGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $210K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Provenance Wealth Advisors held 201 shares of Regeneron Pharmaceuticals worth $125K as of Q2 2026.
Provenance Wealth Advisors bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
Regeneron Pharmaceuticals made up 0.01% of Provenance Wealth Advisors's portfolio in Q2 2026, its #167 holding.
Provenance Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Provenance Wealth Advisors's Regeneron Pharmaceuticals position peaked at $210K in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.